BIIB250103C147000
- 0.00
- 0.000.00%
Biogen Newsroom
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
HealthTech Business Organisation Study: How to Organize Digital Health Businesses, Especially at Large Pharma and MedTech Companies - ResearchAndMarkets.com
Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $231
Biogen Price Target Lowered to $231 From $260 at RBC Capital
RBC Cuts Price Target on Biogen to $231 From $260, Keeps Outperform Rating
Market Climbed Monday Just Past Santa Rally High Water Mark | Wall Street Today
CES Tech Conference Week Starts with Nvidia and Chips Climbing | Live Stock
Healthcare Sector's 2024 Gainers and Losers: Intuitive Surgical, Boston Scientific Tops Chart
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
Santa Claus Came Without Rallying the Troops | Live Stock
Express News | Biogen : Guggenheim Cuts Target Price to $190 From $245
17 Analysts Assess Biogen: What You Need To Know
Piper Sandler Downgrades Biogen to Neutral, Lowers Price Target to $138
Biogen Analyst Ratings
Piper Sandler Downgrades Biogen, Slashes PT by $177 Amid Transition Challenges
These Battered S&P 500 Stocks Could Be Ripe for a Turnaround in 2025
Express News | Biogen : Piper Sandler Cuts to Neutral From Overweight